Literature DB >> 8496689

Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in a verotoxin 1-like disease in pigs.

B Boyd1, G Tyrrell, M Maloney, C Gyles, J Brunton, C Lingwood.   

Abstract

All members of the verotoxin (VT) family specifically recognize globo-series glycolipids on the surface of susceptible cells. Those toxins that are associated with human disease, VT1, VT2, and VT2c, bind to globotriaosyl ceramide (Gb3) while VT2e, which is associated with edema disease of swine, binds preferentially to globotetraosyl ceramide (Gb4). We were recently able to identify, using site-directed mutagenesis, amino acids in the binding subunit of these toxins that are important in defining their glycosphingolipid (GSL) binding specificity (Tyrrell, G. J., K. Ramotar, B. Boyd, B. W. Toye, C. A. Lingwood, and J. L. Brunton. 1992. Proc. Natl. Acad. Sci. USA. 89:524). The concomitant mutation of Gln64 and Lys66 in the VT2e binding subunit to the corresponding residues (Glu and Gln, respectively) found in VT2 effectively converted the GSL binding specificity of the mutant toxin from Gb4 to Gb3 in vitro. We now report that the altered carbohydrate recognition of the mutant toxin (termed GT3) has biological significance, resulting in a unique disease after intravascular injection into pigs as compared with classical VT2e-induced edema disease. The tissue localization of radiolabeled GT3 after intravascular injection was elevated in neural tissues compared with VT2e accumulation, while localization of GT3 to the gastrointestinal tract was relatively reduced. Accordingly, the pathological lesions after challenge with GT3 involved gross edema of the cerebrum, cerebellum, and brain stem, while purified VT2e caused hemorrhage and edema of the cerebellum, and submucosa of the stomach and large intestine. In addition, both radiolabeled toxins bound extensively to tissues not directly involved in the pathology of disease. VT2e, unlike GT3 or VT1, bound extensively to red cells, which have high levels of Gb4. The overall tissue distribution of VT2e was thus found to be influenced by regional blood flow to each organ and not solely by the Gb4 levels of these tissues. Conversely, the distribution of GT3 (and VT1), which cleared more rapidly from the circulation, correlated with respective tissue Gb3 levels rather than blood flow. These studies indicate the primary role of carbohydrate binding specificity in determining systemic pathology, suggest that the red cells act as a toxin carrier in edema disease, and indicate that red cell binding does not protect against the pathology of systemic verotoxemia.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8496689      PMCID: PMC2191045          DOI: 10.1084/jem.177.6.1745

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  19 in total

1.  Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide.

Authors:  T Waddell; A Cohen; C A Lingwood
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Susceptibility to verotoxin as a function of the cell cycle.

Authors:  A Pudymaitis; C A Lingwood
Journal:  J Cell Physiol       Date:  1992-03       Impact factor: 6.384

3.  Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron.

Authors:  K Ramotar; B Boyd; G Tyrrell; J Gariepy; C Lingwood; J Brunton
Journal:  Biochem J       Date:  1990-12-15       Impact factor: 3.857

4.  Comparison of the glycolipid receptor specificities of Shiga-like toxin type II and Shiga-like toxin type II variants.

Authors:  J E Samuel; L P Perera; S Ward; A D O'Brien; V Ginsburg; H C Krivan
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

5.  Globotriosyl ceramide is specifically recognized by the Escherichia coli verocytotoxin 2.

Authors:  T Waddell; S Head; M Petric; A Cohen; C Lingwood
Journal:  Biochem Biophys Res Commun       Date:  1988-04-29       Impact factor: 3.575

6.  The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

Authors:  S E Richardson; M A Karmali; L E Becker; C R Smith
Journal:  Hum Pathol       Date:  1988-09       Impact factor: 3.466

7.  Modification of the glycolipid-binding specificity of vero cytotoxin by polymyxin B and other cyclic amphipathic peptides.

Authors:  S Head; K Ramotar; C Lingwood
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

8.  Globotetraosylceramide is recognized by the pig edema disease toxin.

Authors:  S DeGrandis; H Law; J Brunton; C Gyles; C A Lingwood
Journal:  J Biol Chem       Date:  1989-07-25       Impact factor: 5.157

9.  Alteration of the carbohydrate binding specificity of verotoxins from Gal alpha 1-4Gal to GalNAc beta 1-3Gal alpha 1-4Gal and vice versa by site-directed mutagenesis of the binding subunit.

Authors:  G J Tyrrell; K Ramotar; B Toye; B Boyd; C A Lingwood; J L Brunton
Journal:  Proc Natl Acad Sci U S A       Date:  1992-01-15       Impact factor: 11.205

10.  Crystal structure of the cell-binding B oligomer of verotoxin-1 from E. coli.

Authors:  P E Stein; A Boodhoo; G J Tyrrell; J L Brunton; R J Read
Journal:  Nature       Date:  1992-02-20       Impact factor: 49.962

View more
  22 in total

1.  Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs.

Authors:  T E Waddell; B L Coomber; C L Gyles
Journal:  Can J Vet Res       Date:  1998-04       Impact factor: 1.310

2.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro.

Authors:  M Bitzan; S Richardson; C Huang; B Boyd; M Petric; M A Karmali
Journal:  Infect Immun       Date:  1994-08       Impact factor: 3.441

3.  Globotriaosyl ceramide modulates interferon-alpha-induced growth inhibition and CD19 expression in Burkitt's lymphoma cells.

Authors:  M D Maloney; B Binnington-Boyd; C A Lingwood
Journal:  Glycoconj J       Date:  1999-12       Impact factor: 2.916

4.  Cattle lack vascular receptors for Escherichia coli O157:H7 Shiga toxins.

Authors:  I M Pruimboom-Brees; T W Morgan; M R Ackermann; E D Nystrom; J E Samuel; N A Cornick; H W Moon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-12       Impact factor: 11.205

5.  Shiga toxin binding to isolated porcine tissues and peripheral blood leukocytes.

Authors:  Kellie R K Winter; William C Stoffregen; Evelyn A Dean-Nystrom
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

6.  Identification of a novel streptococcal adhesin P (SadP) protein recognizing galactosyl-α1-4-galactose-containing glycoconjugates: convergent evolution of bacterial pathogens to binding of the same host receptor.

Authors:  Annika Kouki; Sauli Haataja; Vuokko Loimaranta; Arto T Pulliainen; Ulf J Nilsson; Jukka Finne
Journal:  J Biol Chem       Date:  2011-09-09       Impact factor: 5.157

7.  Sodium deoxycholate facilitates systemic absorption of verotoxin 2e from pig intestine.

Authors:  T E Waddell; C L Gyles
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

8.  Binding of shiga toxin 2e to porcine erythrocytes in vivo and in vitro.

Authors:  Ilze Matise; Nancy A Cornick; James E Samuel; Harley W Moon
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Clonal relatedness of Shiga-like toxin-producing Escherichia coli O101 strains of human and porcine origin.

Authors:  S Franke; D Harmsen; A Caprioli; D Pierard; L H Wieler; H Karch
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

10.  Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Authors:  Abhineet S Sheoran; Susan Chapman; Pradeep Singh; Arthur Donohue-Rolfe; Saul Tzipori
Journal:  Infect Immun       Date:  2003-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.